solid driven strong global dupi sale improv sni collabor
profit posit pivot data libtayo nsclc unlock lucr
market opportun kevzara data sever mix
neutral antibodi program promis ad libtayo nsclc
take dupix uptak strong despit differenti
profil across sever indic think dupix continu see growth benefit
at-hom self-administr
encouragingli strong driven minim disrupt eylea impact
tangibl april demand y/i basi sale eylea ex-u impact
price cut see strong tailwind recent safeti issu novarti beovu
solid market growth recent launch eylea pre-filled syring account
use
view libtayo long-term growth driver recent data nsclc robust
compar keytruda although nsclc highli competit given keytruda
entrench posit think libtayo fast follow robust data conced
drug face tough headwind ad singl digit share
segment posit pivot data unlock anoth lucr market submiss
libtayo indic expect anticip launch libtayo
nsclc drive long-term growth
sni collabor also becom highli profit primarili driven dupix
acceler point
regn program promis recent data kevzara portion
sever patient intub equivoc kol
skeptic potenti therapi given patient advanc
market modest global note portion regeneron
studi critic patient expect report data june sni separ ex-
us broad popul expect report data
optimist regn antibodi cocktail regeneron
leader space proven record develop safe effect antibodi
treatment ebola mer regn antibodi therapi target treatment
prophylaxi broader commerci potenti studi commenc june
differ patient segment possibl initi result eman late summer
earli fall regeneron capac dose
pleas see page report import disclosur
see sever year beat estim domin market eylea
brink face tough competit novartiss beovu howev risk quickli
diminish given emerg toxic concern beovu anticip eylea
continu growth asset like face competit roch
faricimab phase on-going biosimilar entri us/eu dupix
see bright futur ahead atop dermat asthma allergic-typ disord
like earli stage bispecif io pipelin opportun target
competit segment posit pivot data libtayo nsclc unlock
lucr opportun despit enthusiasm dupix due valuat restraint
market perform rate
us approv dupi pediatr ad
pivot dupi data pediatr asthma
dupi data part eoe mid
evinacumab bla submiss hofh
data b-cell malign
global eylea sale
compound-annual-growth-rate
dupix achiev
regeneron antibodi
gener annual
revenu
eylea sale reach without
competit
dupix sale achiev
peanut grass allergi work
approv achiev
sale
eylea reach
dupix fail take reach
success
regeneron first three commerci product fusion protein develop use trap
technolog platform eylea aflibercept becom market lead brand anti-vegf
dme regeneron second technolog platform velocisuit allow compani
develop highli specif fulli human monoclon antibodi lead product includ
dupix approv march atop dermat octob asthma march
adolesc ad june crswnp clinic trial indic praluent
approv hypercholesterolemia kevzara approv may ra libtayo
approv cscc octob program regeneron pipelin includ
fasinumab osteoarthr bispecif antibodi cancer
pt base vs previous ep vs
rais pt made sever chang increas long-term sale
estim ad libtayo sale nsclc use higher price-to-earnings
multipl due improv profit better visibl libtayo new indic
ep lower due anticip impact eylea slightli increas opex
dramat increas share count
increas share count vs primarili due employe
exercis stock option partial off-set compani repurchas share
expect share count rang assum stock
remain current level
ad sale libtayo nsclc model assum late
launch new pt base vs previous price-to-earnings multipl
ep
due restrict antibodi collabor sanofi model opex sanofi
antibodi collabor decreas translat
ramp regeneron share profit
pleas see note earlier today result
today report pivot studi libtayo show clinic meaning
durabl respons advanc basal cell carcinoma patient
progress intoler hedgehog pathway inhibitor hhi therapi
notabl drug show durabl diseas control rate dcr new safeti
lucr opportun patient us ex-u
high unmet medic need hhi respons
note today /sni plan regulatori submiss model
approv launch late first regimen approv
anticip libtayo achiev peak global sale
nsclc multi-billion opportun albeit highli competit recal libtayo os data
nsclc robust compar keytruda patient
second monotherapi approv nsclc think libtayo find nich
share fast follow robust data
also confirm today regulatori submiss nsclc us eu
expect model approv launch nsclc late conserv
peak penetr elig patient translat peak global sale
notabl libtayo second trial nsclc combin studi expect
fulli enrol vs mid previous
pleas see recent note posit libtayo data nsclc
bloomberg regeneron cowen compani
cowen compani
mm except per share product collabor zaltrap ww sanofi antibodi reimburs praluent world-wide sale kevzara world-wide dupix dupix ex-u dupix world-wide libtayo ex-u reimburs commerci expens regeneron share antibodi commerci profit ex collabor eylea ex-u eylea reimburs amort mileston eylea ex-u profit collabor ex-u non- reimburs non- unreimburs stock comp expens includ non- antibodi commerci expens non- stock comp expens includ oper incom expens total expensepre-tax rate incom net incom net incom share quarterli cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
regeneron deriv great major product revenu one product eylea
forecast sale product difficult outlook could alter
competit clinic develop failur reimburs chang new competit
could also impact sale estim pipelin product might fail develop risk
regeneron stock price includ clinic develop regulatori price commerci
challeng may prevent financi forecast materi
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
